Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17063326 | 0.96 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17063250 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL19461283 | 0.86 | GRIN2B (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL19461486 | 0.85 | GRIN2B (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17078958 | 0.84 | HTR7 (0.44) | ACHEF2 | |
| SCHEMBL17063266 | 0.80 | POLB (0.50) | SMN1; SMN2NPC1GRIN2BACHEF2 | |
| SCHEMBL4828209 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17453902 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17453723 | 0.79 | GRIN2B (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17063383 | 0.79 | KDM4E (0.46) | ACHEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3172195-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RXRA | SMN1; SMN2 235/4885NPC1 1453/4885RAB9A 1256/4885 |
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RARG | SMN1; SMN2 645/4885NPC1 628/4885RAB9A 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.